Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview

References

• Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon a-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N. Engl. J. Med.338, 1272–1278 (1998).
   PubMed Web of Science ®Google Scholar
• Negrier S, Maral J, Drevon M et al. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J. Sci. Am.6(Suppl. 1), S93–S98 (2000).
   PubMedGoogle Scholar
• Negrier S, Perol D, Ravaud A et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. J. Clin. Oncol.23, LBA4511 (2005) (Meeting Abstract).
   Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med.356, 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Szczylik C, Demkow T et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naive patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol.24, 4501 (2006) (Meeting Abstract).
   Google Scholar
• Carlomagno F, Anaganti S, Guida T et al. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl Cancer Inst.98, 326–334 (2006).
   PubMed Web of Science ®Google Scholar
• Levy AP, Pauloski N, Braun D et al. Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006). Proc. Am. Assoc. Cancer Res.47, 213 (2006).
   Google Scholar
• Rini BI. VEGF-targeted therapy in metastatic renal cell carcinoma. Oncologist10, 191–197 (2005).
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64, 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Panka DJ, Wang W, Atkins MB, Mier JW. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res.66, 1611–1619 (2006).
   PubMed Web of Science ®Google Scholar
• Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J. Biol. Chem.280, 35217–35227 (2005).
   PubMed Web of Science ®Google Scholar
• Yu C, Bruzek LM, Meng XW et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene24, 6861–6869 (2005).
   PubMed Web of Science ®Google Scholar
• Strumberg D, Awada A, Hirte H et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur. J. Cancer42, 548–556 (2006).
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24, 2505–2512 (2006).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356, 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Eisen T, Bukowski RM, Staehler M et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival. J. Clin. Oncol.24, 4524 (2006) (Meeting Abstract).
   Google Scholar
• Bukowski RM, Eisen T, Szczylik C et al. Final results of the randomized Phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J. Clin. Oncol.25, 5023 (2007) (Meeting Abstract).
   Web of Science ®Google Scholar
• Steinbild S, Mross K, Morant D et al. Phase II study of sorafenib (BAY 43-9006) in hormone-refractory patients with prostate cancer: a study of the Central European Society for Anticancer Drug Research–EWIV (CESAR). J. Clin. Oncol.24, 3094 (2006) (Meeting Abstract).
   Google Scholar
• Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome. Incidence, recognition and management. Am. J. Clin. Dermatol.1, 225–234 (2000).
   PubMedGoogle Scholar
• Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol.6, 491–500 (2005).
   PubMed Web of Science ®Google Scholar
• Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43-9006. J. Clin. Oncol.24, 1363–1369 (2006).
   PubMed Web of Science ®Google Scholar
• Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J. Clin. Oncol.24, 1329–1331 (2006).
   PubMed Web of Science ®Google Scholar
• Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology17, 23–28 (2003).
   PubMedGoogle Scholar
• Schoeffski P, Wolter P, Himpe U et al. Sunitinib-related thyroid dysfunction: a single-center retrospective and prospective evaluation. J. Clin. Oncol.24, 3092 (2006) (Meeting Abstract).
   Web of Science ®Google Scholar
• Shaheen PE, Tamaskar IR, Salas RN et al. Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. J. Clin. Oncol.24, 4605 (2006) (Meeting Abstract).
   Google Scholar
• Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl Cancer Inst.99, 81–83 (2007).
   PubMed Web of Science ®Google Scholar
• Tamaskar IR, Unnithan J, Garcia JA et al. Thyroid function test (TFT) abnormalities in patients (pts) with metastatic renal cell carcinoma (RCC) treated with sorafenib. J. Clin. Oncol.25, 5048 (2007) (Meeting Abstract).
   Google Scholar
• Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med.349, 427–434 (2003).
   PubMed Web of Science ®Google Scholar
• Escudier B, Koralewski P, Pluzanska A et al. A randomized, controlled, double-blind Phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. J. Clin. Oncol.25, 3 (2007) (Meeting Abstract).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-a (IFN) or the combination of TEMSR+IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J. Clin. Oncol.24, LBA4 (2006) (Meeting Abstract).
   Google Scholar
• Dutcher JP, Szczylik C, Tannir N et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J. Clin. Oncol.25, 5033 (2007) (Meeting Abstract).
   Google Scholar
• Szczylik C, Dmkow T, Staehler M et al. Randomized Phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J. Clin. Oncol.25, 5025 (2007) (Meeting Abstract).
   Web of Science ®Google Scholar
• Hutson TE, Quinn DI. Cytokine therapy: a standard of care for metastatic renal cell carcinoma? Clin. Genitourin. Cancer4, 181–186 (2005).
   PubMedGoogle Scholar
• Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol.21, 3127–3132 (2003).
   PubMed Web of Science ®Google Scholar
• Azad NS, Posadas EM, Kwitkowski VE et al. Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. J. Clin. Oncol.24, 3004 (2006) (Meeting Abstract).
   Web of Science ®Google Scholar
• Flaherty KT, Brose M, Schuchter L et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J. Clin. Oncol.22, 7507 (2004) (Abstract).
   Google Scholar
• Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin. Oncol.33, 392–406 (2006).
   PubMed Web of Science ®Google Scholar
• Kupsch P, Henning BF, Passarge K et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin. Colorectal Cancer5, 188–196 (2005).
   PubMedGoogle Scholar
• Ryan CW, Goldman BH, Lara PN Jr et al. Sorafenib plus interferon-a2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. J. Clin. Oncol.24, 4525 (2006) (Meeting Abstract).
   Google Scholar
• Escudier B, Lassau N, Angevin E et al. Phase I trial of sorafenib in combination with IFN α-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin. Cancer Res.13, 1801–1809 (2007).
   PubMed Web of Science ®Google Scholar
• Patel PH, Kondagunta GV, Redman BG et al. Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol.25, 5097 (2007) (Meeting Abstract).
   Google Scholar
• Knox JJ, Figlin RA, Stadler WM et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: safety and efficacy. J. Clin. Oncol.25, 5011 (2007) (Meeting Abstract).
   Google Scholar
• Ryan CW, Bukowski RM, Figlin RA et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: long-term outcomes in first-line patients (pts). J. Clin. Oncol.25, 5096 (2007) (Meeting Abstract).
   Google Scholar
• Stadler WM, Figlin RA, Ernstoff MS et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC). J. Clin. Oncol.25, 5036 (2007) (Meeting Abstract).
   Web of Science ®Google Scholar